These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 36366329)
1. Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior. Kodera S; Niimi Y; Rashed EA; Yoshinaga N; Toyoda M; Hirata A Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366329 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224 [TBL] [Abstract][Full Text] [Related]
5. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100 [TBL] [Abstract][Full Text] [Related]
7. Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan. Kodera S; Rashed EA; Hirata A Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335062 [TBL] [Abstract][Full Text] [Related]
8. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. Mimura W; Ishiguro C; Maeda M; Murata F; Fukuda H Open Forum Infect Dis; 2022 Dec; 9(12):ofac636. PubMed ID: 36589480 [TBL] [Abstract][Full Text] [Related]
10. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States. Adams K; Rhoads JP; Surie D; Gaglani M; Ginde AA; McNeal T; Ghamande S; Huynh D; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hicks M; Hager DN; Ali H; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Lauring AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Chappell JD; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Lindsell CJ; Hart KW; Lester SN; Thornburg NJ; Park S; McMorrow ML; Patel MM; Tenforde MW; Self WH medRxiv; 2022 Jun; ():. PubMed ID: 35734090 [No Abstract] [Full Text] [Related]
11. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007 [TBL] [Abstract][Full Text] [Related]
12. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. Baum U; Poukka E; Leino T; Kilpi T; Nohynek H; Palmu AA BMC Infect Dis; 2022 Nov; 22(1):816. PubMed ID: 36335289 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022. Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708 [TBL] [Abstract][Full Text] [Related]
14. The strategy behind Japan's response to COVID-19 from 2020-2021 and future challenges posed by the uncertainty of the Omicron variant in 2022. Song P; Karako T Biosci Trends; 2022 Jan; 15(6):350-352. PubMed ID: 34980786 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. Yang W; Shaman J medRxiv; 2021 Nov; ():. PubMed ID: 34845460 [TBL] [Abstract][Full Text] [Related]
16. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022. McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757 [TBL] [Abstract][Full Text] [Related]
18. Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine. Anichini G; Terrosi C; Gori Savellini G; Gandolfo C; Barbagli F; Carta GA; Fabrizi S; Miceli GB; Cusi MG Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146590 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697 [TBL] [Abstract][Full Text] [Related]
20. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]